Skip to main content
. 2020 Apr;9(1):40–49. doi: 10.29252/rbmb.9.1.40

Table 2.

Clinicopathological data

Characteristic N (%)
Stage I 4 (6.3)
II 47 (73.4)
III 8 (12.5)
CD34 low 28 (43.8)
moderate 27 (42.2)
high 9 (14.1)
Histologic grade I 10 (16.1)
II 46 (74.2)
III 6 (9.7)
ER status Positive 38 (59.4)
Negative 24 (37.5)
PR status Positive 38 (59.4)
Negative 24 (37.5)
HER2 status Positive 29 (45.3)
Negative 33 (51.6)
Tumor size <2 cm 5 (7.8)
2-5cm 54 (84.4)
Age <40 years 8 (12.5)
≥40 years 52 (81.3)
Histological Type aIDCA 57 (89.1)
bILCA 4 (6.3)
Node status Positive 29 (45.3)
Negative 30 (46.9)
Ki67 Positive 10 (15.6)
Negative 52 (81.3)
Annexin V Positive 10 (20.8)
Negative 38 (79.2)
Subtype luminal A 36 (56.3)
luminal B 11 (17.2)
Basal Like 13 (20.3)
ERBB2 2 (3.1)

aIDCA = Invasive Ductal Carcinoma.

bILCA= Invasive Lobular Carcinoma.

* Clinicopathological data of a number of patients not available.